FDA Approved: NORVASC — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

FDA approved a supplemental application for Norvasc (amlodipine besylate) submitted by Viatris Specialty LLC to update the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease
• Hypertension

Drugs mentioned

• NORVASC (amlodipine besylate)

Snippet

SUPPL AP for NORVASC (AMLODIPINE BESYLATE)